AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO (Revised)
AstraZeneca’s (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triple… #financialfreedomllc #businesstip…
